Key result
Circulating endothelial progenitor cells predict post-MI remodeling and risk, though definitional uncertainties limit clinical use.
Why the study?
Understanding of endothelial progenitor cells is limited by lack of an unequivocal definition, complicating their clinical application in cardiovascular diseases.
This review highlights the prognostic potential of endothelial progenitor cells in cardiovascular disease while emphasizing that definitional uncertainties currently limit their clinical application.
Several physiological and pathophysiological stimuli or drugs modulate endothelial progenitor cell (EPC) mobilization. Moreover, levels of circulating EPCs predict cardiovascular risk and left ventricular remodelling after myocardial infarction. Nevertheless, our understanding in this field is complicated by lack of an unequivocal definition of EPCs, thus limiting their clinical applications. This review summarizes current knowledge and uncertainties on EPC characterization and mobilization in the attempt to define their role in the management of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2008) conducted a review in Cardiovascular diseases. Endothelial progenitor cells (EPCs) was evaluated. Circulating endothelial progenitor cells predict cardiovascular risk and left ventricular remodeling after myocardial infarction, but clinical applications remain limited by definitional uncertainties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: